The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax

The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling cascade is an important therapeutic target for lymphomas. Rapamycin-derivates as allosteric mTOR complex 1 (TORC1) inhibitors have shown moderate preclinical and clinical anti-lymphoma activity. Here, we asse...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancers (Basel)
Glavni autori: Tarantelli, Chiara, Gaudio, Eugenio, Hillmann, Petra, Spriano, Filippo, Sartori, Giulio, Aresu, Luca, Cascione, Luciano, Rageot, Denise, Kwee, Ivo, Beaufils, Florent, Zucca, Emanuele, Stathis, Anastasios, Wymann, Matthias P., Cmiljanovic, Vladimir, Fabbro, Doriano, Bertoni, Francesco
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6627883/
https://ncbi.nlm.nih.gov/pubmed/31167506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11060775
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items